Anti-EGFR/VEGFR2 BsAb showed enhanced anti-tumor activities via multiple mechanisms of action in both in vitro and in vivo models of TNBC, suggesting that co-targeting of EGFR and VEGFR2 with this BsAb can result in synergistic anti-tumor activities than single agent treatment. This evidence concerns the gene KDR and neoplasm.